Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Juni 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

EMERYVILLE, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
31. Mai 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Participate in Jefferies 2016 Healthcare Conference

EMERYVILLE, Calif., May 31, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders,...
10. Mai 2016 16:01 ET | Quelle: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results

EMERYVILLE, Calif., May 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
05. Mai 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time New Clinical Data Presented at 14th International Child Neurology Congress on the Use of Low-Dose Fenfluramine...
03. Mai 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10

EMERYVILLE, Calif., May 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
21. April 2016 08:00 ET | Quelle: Zogenix, Inc.

New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress

EMERYVILLE, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
10. März 2016 16:00 ET | Quelle: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results

EMERYVILLE, Calif., March 10, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
04. März 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Release Fourth Quarter and Full-Year 2015 Financial Results and Host Conference Call and Webcast on March 10

EMERYVILLE, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
03. Februar 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference

EMERYVILLE, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...
19. Januar 2016 08:00 ET | Quelle: Zogenix, Inc.

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome

EMERYVILLE, Calif., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today...

Vorherige Seite

Nächste Seite